Advertisement

Clinical Drug Investigation

, Volume 26, Issue 6, pp 351–356 | Cite as

Montelukast Decreases Plasma Endothelin-1 and Serum Eosinophil Cationic Protein Levels in Paediatric Atopic Asthma

  • Frantisek Kopřiva
  • Anna Janošťáková
  • Szotkowská Jarmila
  • Martin Zápalka
  • Marián Hajduch
Original Research Article

Abstract

Background and objective: Endothelin-1 (ET-1) is produced by vascular endothelial cells and epithelial cells, T-lymphocytes and phagocytes. Increased ET-1 levels have been demonstrated in the bronchial epithelium of asthma patients. In vitro, ET-1 stimulates mucus secretion, activates proinflammatory cells — macrophages and mast cells — and serves as a mitogenic stimulus for fibroblasts and smooth muscle. In addition, ET-1 activates phospholipase 2. Compared with healthy individuals, asthma patients have increased ET-1 levels during an attack and following stabilisation. Our study was designed to examine plasma ET-1 (P-ET) levels in paediatric atopic patients newly diagnosed with persistent mild bronchial asthma and 1 month after initiation of montelukast therapy.

Methods: Patients’ histories were examined, and their blood eosinophil leucocyte count and levels of total serum immunoglobulin E (S-IgE), serum eosinophil cationic protein (S-ECP) and P-ET were determined. Thirty-six patients with persistent mild bronchial asthma were treated with the leukotriene receptor antagonist montelukast, administered once a day for 4 weeks. Second P-ET and S-ECP level determinations were made 4 weeks later with all the children included in the study. P-ET levels were also determined in a group of 27 healthy children who had no atopy in their medical histories and were taking no drugs (including montelukast), and who served as controls.

Results: The mean ± SD pretreatment P-ET level in the 36 study children was 11.542 ± 6.408 pg/L, and this decreased to 5.636 ± 4.419 pg/L after 1 month’s therapy with montelukast (statistically significant difference; p < 0.0001). Both of these values were significantly higher (p < 0.0001 and p < 0.031, respectively) than the mean level in the control group of 27 children (3.543 ± 2.497 pg/L). The mean pretreatment S-ECP level was 35.78 ± 19.58 μg/L, and this decreased to 19.54 ± 13.86 μg/L after 1 month’s therapy (p < 0.001).

Conclusions: This study demonstrated a decrease in P-ET levels in children with mild asthma receiving montelukast. This indicates a reduction in the severity of the inflammatory response and, hence, provides evidence for the anti-inflammatory effect of montelukast. Monitoring both ET-1 and ECP levels at regular follow-up may be useful in assessing these two facets of activity of chronic inflammation in bronchial asthma.

Keywords

Montelukast Eosinophil Cationic Protein Mild Persistent Bronchial Asthma Eosinophil Cationic Protein Level Serum Eosinophil Cationic Protein 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

This work was supported by MSM grant 6198959216 and MSD, s.r.o Czech Republic. The authors have no potential conflicts of interest that are directly relevant to the contents of this study.

References

  1. 1.
    Borish L. Endothelin-1: a useful marker for asthmatic inflammation? Ann Allergy Asthma Immunol 2002 Apr; 88(4): 345–6PubMedCrossRefGoogle Scholar
  2. 2.
    Carratu P, Scuri M, Stybio JI, et al. ET-1 induces mitogenesis in ovine airway smooth muscle cells via ETA and ETB receptors. Am J Physiol 1997 May; 272 (5 Pt 1): L1021–4PubMedGoogle Scholar
  3. 3.
    Dube J, Charlie J, Dube C, et al. Synergistic action of endothelin (ET)-l on the activation of bronchial fibroblast isolated from normal and asthmatic subjects. Int J Exp Pathol 2000 Dec; 81(6): 429–37PubMedCrossRefGoogle Scholar
  4. 4.
    Goldie RG, Henry PJ. Endothelins and asthma. Life Sci 1999; 65(1): 1–15PubMedCrossRefGoogle Scholar
  5. 5.
    NHLBI/WHO Workshop Report: Global strategy for asthma management and prevention. Issued January 1995. NIH Publication No. 02-3659. Updated 2002Google Scholar
  6. 6.
    Zapletal A, Zemanek M, Paul T. Lung function in children and adolescents: methods and reference values. In Progress in Respiratory Disease. Basel: Herzog 1987Google Scholar
  7. 7.
    Hay DWP, Compton CH. Endothelin antagonists. In: Hansel TT, Barnes PJ, editors. New drugs for asthma, allergy and COPD. Prog Respir Res 2001; 31: 141–4CrossRefGoogle Scholar
  8. 8.
    EL-Gamal Y, Hossny E, Awwad K, et al. Plasma endothelin-1 immunoreactivity in asthmatic children. Ann Allergy Asthma Immunol 2002 Apr; 88(4): 370–3PubMedCrossRefGoogle Scholar
  9. 9.
    Goldie RG, Knott PG, Carr M, et al. The endothelins in the pulmonary system. Pulm Pharmacol 1996 Apr; 9(2): 69–93PubMedCrossRefGoogle Scholar
  10. 10.
    Grebski E, Wu J, Wuthrich B, et al. Does eosinophil cationic protein in sputum and blood reflect bronchial inflammation and obstruction in allergic asthmatics? J Investig Allergol Clin Immunol 1999; 9: 82–8PubMedGoogle Scholar
  11. 11.
    Holla LL, Vasku A, Lzakovic V, et al. Variants of endothelin-1 gene in atopic disease. J Investig Allergol Clin Immunol 2001; 11(3): 193–8PubMedGoogle Scholar
  12. 12.
    Dworski R, Szczeklik A, Prokop A, et al. Urinary levels of endothelin-1 increase in patients with aspirin-induced asthma after inhaled challenge with asthma [abstract]. Am J Respir Crit Care Med 1998; 157: A718Google Scholar
  13. 13.
    Welliever II RC, Welliever RC. Increased production of IFN-gamma and cysteinyl leukotrienes in virus-induced wheezing. J Allergy Clin Immunol 1999 Apr; 103(4): 630–6CrossRefGoogle Scholar
  14. 14.
    Sarau HM, Ames RS, Chambers J, et al. Identification, molecular cloning, expression, and characterization of cysteinyl leukotriene receptor. Mol Pharmacol 1999 Sep; 56(3): 657–63PubMedGoogle Scholar
  15. 15.
    Finsnes F, Lyberg T, Christensen G, et al. Leukotriene antagonism reduces the generation of endothelin-1 and inteferongama and inhibits eosinophilic airway inflammation. Respir Med 2002; 96(11): 901–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Frantisek Kopřiva
    • 1
  • Anna Janošťáková
    • 2
  • Szotkowská Jarmila
    • 3
  • Martin Zápalka
    • 1
  • Marián Hajduch
    • 2
  1. 1.Department of PaediatricsPalacký University Medical School and University HospitalOlomoucCzech Republic
  2. 2.Laboratory of Experimental MedicineUniversity Hospital and Palacký UniversityOlomoucCzech Republic
  3. 3.Department of ImmunologyUniversity Hospital and Palacký UniversityOlomoucCzech Republic

Personalised recommendations